CoChat

HER3 Alterations in Cancer and Potential Clinical Implications

Open access

The DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.

Abstract

In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer disease progression. HER3 mutations occur at a rate up to ~10% of tumors dependent on the tumor type. With patient tumors routinely sequenced for gene alterations in recent years, we have focused on HER3 mutations in bladder, breast, colon, and lung cancers particularly in response to targeted therapies and the potential to become a resistance mechanism. There are currently several HER3 targeting drugs in the pipeline, possibly improving outcomes for cancer patients with tumors containing HER3 activation and/or alterations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14246174

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a) HER3 dimerizes with other RTKs, most notably HER2, to activate downstream pathways involved in cell growth, survival, and signaling. (b) HER3 has several common mutations located across the four extracellular and kinase domains, as indicated by red stars. P: phosphorylation site, and NRG indicates the HER3 ligand neuregulin. Figure generated using BioRender.
Figure 1 (a) HER3 dimerizes with other RTKs, most notably HER2, to activate downstream pathways involved in cell growth, survival, and signaling. (b) HER3 has several common mutations located across the four extracellular and kinase domains, as indicated by red stars. P: phosphorylation site, and NRG indicates the HER3 ligand neuregulin. Figure generated using BioRender.CC BY · PubMed Central
Figure 2 The frequency of HER3 alterations as seen in bladder (n = 2419), breast (n = 8615), colorectal (n = 4453), and lung (n = 7204) cancers across different subtypes and multiple nonredundant studies. Figure rendered using cBioPortal [27,28].
Figure 2 The frequency of HER3 alterations as seen in bladder (n = 2419), breast (n = 8615), colorectal (n = 4453), and lung (n = 7204) cancers across different subtypes and multiple nonredundant studies. Figure rendered using cBioPortal [27,28].CC BY · PubMed Central
Figure 3 The frequency of HER3 mutations in bladder cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 2419). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].
Figure 3 The frequency of HER3 mutations in bladder cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 2419). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].CC BY · PubMed Central
Figure 4 The frequency of HER3 mutations in breast cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 8615). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].
Figure 4 The frequency of HER3 mutations in breast cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 8615). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].CC BY · PubMed Central
Figure 5 The frequency of HER3 mutations in colorectal cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 4453). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].
Figure 5 The frequency of HER3 mutations in colorectal cancer and their locations within the receptor. Figure rendered in cBioPortal using multiple studies (n = 4453). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].CC BY · PubMed Central
Figure 6 The frequency of HER3 mutations in lung cancer and their locations within the HER3 receptor. Figure rendered in cBioPortal using multiple studies (n = 7204). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].
Figure 6 The frequency of HER3 mutations in lung cancer and their locations within the HER3 receptor. Figure rendered in cBioPortal using multiple studies (n = 7204). Gray indicates truncating mutation, green indicates a missense mutation, yellow indicates splice mutation, and brown indicates an in-frame mutation [27,28].CC BY · PubMed Central
Figure 7 The main categories of HER3 targeting therapies include monoclonal antibodies, multitargeted antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors (TKIs). Monoclonal antibodies bind to the extracellular domain of HER3. Multi-targeted antibodies include bispecific antibodies which combine two different antigen-binding sites in a single antibody. Antibody-Drug Conjugates are monoclonal antibodies chemically linked to a chemotherapeutic drug. Tyrosine kinase inhibitors are small molecules inhibitors that block tyrosine kinase activity. Figure generated using BioRender.
Figure 7 The main categories of HER3 targeting therapies include monoclonal antibodies, multitargeted antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors (TKIs). Monoclonal antibodies bind to the extracellular domain of HER3. Multi-targeted antibodies include bispecific antibodies which combine two different antigen-binding sites in a single antibody. Antibody-Drug Conjugates are monoclonal antibodies chemically linked to a chemotherapeutic drug. Tyrosine kinase inhibitors are small molecules inhibitors that block tyrosine kinase activity. Figure generated using BioRender.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 152 references

Cited by

See all 24

Metadata

Authors
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T.
Affiliations
  • University of Cincinnati (US)
  • Department of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA
  • Harold C. Simmons Comprehensive Cancer Center (US)
Corresponding author
Garrett, Joan T.
Venue
Cancers
Publisher
MDPI AG
Published
2022-12-14
Volume
14
Issue
24
Pages
6174
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4311793976
Cited by
21
References
155
Citations by year
2026: 4 · 2025: 6 · 2024: 10 · 2023: 1
FWCI
0.52
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
American Cancer Society (RSG-20-071-01-TBG)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
HER3, ErbB receptors, bladder cancer, breast cancer, colorectal cancer, lung cancer, tumor progression, targeted therapy resistance, genetic alterations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER3 Alterations in Cancer and Potential Clinical Implications. https://app.cochat.ai/papers/10.3390/cancers14246174
The paper
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022). HER3 Alterations in Cancer and Potential Clinical Implications. Cancers. https://doi.org/10.3390/cancers14246174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.